Breaking News Instant updates and real-time market news.

VRTX

Vertex

$152.01

-0.95 (-0.62%)

, GLPG

Galapagos NV

$115.19

6.36 (5.84%)

07:12
02/13/18
02/13
07:12
02/13/18
07:12

Vertex halted trials in France as protest, says H.C. Wainwright

H.C. Wainwright analyst Andrew Fein says he learned via Twitter and a news article that Vertex Pharmaceuticals (VRTX) decided to discontinue the Phase 3 trials of its triple combination therapy for cystic fibrosis in France due to an inability to reach reimbursement agreement with the French authorities for Orkambi. Releasing patients may inadvertently help Vertex's competitors gain ground, especially Galapagos (GLPG) and Proteostasis (PTI), Fein tells investors in a research note. He keeps a Neutral rating on Vertex shares with a $103 price target.

VRTX

Vertex

$152.01

-0.95 (-0.62%)

GLPG

Galapagos NV

$115.19

6.36 (5.84%)

PTI

Proteostasis

$3.01

0.27 (9.85%)

  • 28

    Feb

VRTX Vertex
$152.01

-0.95 (-0.62%)

02/01/18
LEER
02/01/18
NO CHANGE
Target $190
LEER
Outperform
Vertex price target raised to $190 from $175 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Vertex to $190 from $175 saying "strong" Q4 and triple data offer upside. The analyst reiterates an Outperform rating on the shares.
02/01/18
RBCM
02/01/18
NO CHANGE
Target $200
RBCM
Outperform
Vertex price target raised to $200 from $181 at RBC Capital
RBC Capital RBC Capital analyst Brian Abrahams raised his price target on Vertex to $200 and kept his Outperform rating, saying that Q4 earnings highlighted continued opportunity in the CF market. The analyst adds that the "best-case data from two next-gen correctors show activity even better than game-changing results from first two", setting the stage for pivotal trial starts.
02/01/18
DBAB
02/01/18
NO CHANGE
Target $193
DBAB
Buy
Vertex investors should pay more attention to Galapagos, says Deutsche Bank
Deutsche Bank analyst Navin Jacob raised his price target for Vertex Pharmaceuticals (VRTX) to $193 from $175 following last night's Q4 results and keeps a Buy rating on the shares. The triple efficacy data are better than expected, and create a "very high hurdle" for competitors, Jacob tells investors in a research note. He believes, however, that Vertex investors should be paying more attention to Galapagos NV (GLPG). Galapagos CEO Ono van de Stolpe has "100% confidence" that the company will be getting its first novel triple combo into patients in Q1, Jacob tells investors in a research note after meeting with the executive. The analyst expects some volatility to Vertex shares if Galapagos is able to start the triple trial in Q1. Jacob, however, adds that his math puts Galapagos two-and-a-half years behind Vertex and that the efficacy hurdle is "VERY high."
02/01/18
JEFF
02/01/18
NO CHANGE
Target $195
JEFF
Buy
Jefferies sees Vertex moving higher, ups target to $195
Jefferies analyst Michael Yee raised his price target for Vertex Pharmaceuticals to $195 from $185 and reiterates a Buy rating on the shares following last night's Q4 results. The company's triple pill could triple earnings in the next five years with no biosimilar or generic issues on the horizon, Yee tells investors in a research note. He sees the stock moving higher.
GLPG Galapagos NV
$115.19

6.36 (5.84%)

01/03/18
JEFF
01/03/18
NO CHANGE
Target $185
JEFF
Buy
Vertex competitor's cystic fibrosis update unsurprising, says Jefferies
Jefferies analyst Michael Yee says last night's cystic fibrosis update from Vertex Pharmaceuticals (VRTX) competitor Galapagos NV (GLPG) contained no surprises. None of Galapagos' developments are unexpected, and 2018 remains a period where the Vertex competitor is running a number of "proof of concept" studies to see if it has something, Yee tells investors in a research note. He believes challenges remain for cystic fibrosis competitors because making a triple requires three individual drugs to show minimal drug-drug interactions and have a clean side effect profile. Yee keeps a Buy rating on Vertex with a $185 price target.
09/15/17
STFL
09/15/17
NO CHANGE
Target $120
STFL
Buy
Galapagos NV price target raised to $120 from $101 at Stifel
After hosting a call with two key opinion leaders on idiopathic pulmonary fibrosis, Stifel analyst Adam Walsh noted that the physicians expressed the view that the efficacy of GLPG1690 in the Phase 2 FLORA trial "was as good as one could have hoped for." As a result of the positive physician feedback, he increased his probability of success for '1690 to 15% from 10% and raised his price target on Galapagos to $120 from $101. Walsh keeps a Buy rating on Galapagos shares.
09/14/17
RBCM
09/14/17
INITIATION
Target $98
RBCM
Sector Perform
Galapagos NV initiated with a Sector Perform at RBC Capital
RBC Capital analyst Brian Abrahams started Galapagos NV with a Sector Perform rating and $98 price target.
PTI Proteostasis
$3.01

0.27 (9.85%)

12/12/17
LEER
12/12/17
NO CHANGE
Target $8
LEER
Proteostasis price target raised to $8 from $6 at Leerink
12/12/17
JMPS
12/12/17
NO CHANGE
Target $200
JMPS
Outperform
Proteostasis data not as positive as Vertex, says JMP Securities
JMP Securities analyst Liisa Bayko says Proteostasis Therapeutics' (PTI) CF programs look positive, but not as positive as Vertex (VRTX) at this point. Nonetheless, the analyst acknowledges that it remains early days for Proteostasis and she still needs to see how its internal triple combination will perform. Bayko reiterates an Outperform rating and $200 price target on Vertex shares.
12/12/17
BARD
12/12/17
NO CHANGE
Target $25
BARD
Outperform
Proteostasis price target nearly doubled to $25 at Baird
Baird analyst Brian Skorney noted that Proteostasis (PTI) reported proof-of-concept data for the company's lead drug, PTI-428, that surpassed his expectations and "clearly confirms" that PTI-428 is biologically active. Though not "as mind-blowing as Vertex's triple data," he would argue that the benefit should be taken at face value and that PTI-428 is a first-in-class "amplifier," Skorney tells investors. The analyst raised his price target on Proteostasis to $25 from $13 on his view of the increased probability of success for PTI-428. Proteostasis Therapeutics shares are up 78% in pre-market trading to $4.19.
08/16/17
LEER
08/16/17
NO CHANGE
Target $9
LEER
Outperform
Proteostasis price target lowered to $9 from $17 at Leerink
Leerink analyst Joseph Schwartz lowered his price target for Proteostasis to $9 from $17 but reiterated an Outperform rating on the shares. The analyst notes that competitive developments have raised investor concern about the future of Proteostasis, but believes the company's current market cap of about $60M reflects a worst case scenario that assigns very little if any credit to the company's technology ahead of potentially impactful data in 2H17 and beyond.

TODAY'S FREE FLY STORIES

ELLI

Ellie Mae

$65.08

1.4 (2.20%)

12:54
11/21/18
11/21
12:54
11/21/18
12:54
Hot Stocks
Breaking Hot Stocks news story on Ellie Mae »

HMI Capital reports 5.67%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

GME

GameStop

$12.60

0.3 (2.44%)

12:50
11/21/18
11/21
12:50
11/21/18
12:50
Hot Stocks
GameStop says board still reviewing strategic, financial alternatives »

"This transaction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

GME

GameStop

$12.60

0.3 (2.44%)

12:49
11/21/18
11/21
12:49
11/21/18
12:49
Hot Stocks
GameStop to sell Spring Mobile unit to Prime Communications for $700M »

GameStop (GME) announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

12:45
11/21/18
11/21
12:45
11/21/18
12:45
General news
Breaking General news story  »

Week of 11/21…

GME

GameStop

$12.60

0.3 (2.44%)

12:44
11/21/18
11/21
12:44
11/21/18
12:44
Hot Stocks
Breaking Hot Stocks news story on GameStop »

GameStop trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

OMC

Omnicom

$76.77

1.06 (1.40%)

, WPP

WPP

$54.99

1.4 (2.61%)

12:42
11/21/18
11/21
12:42
11/21/18
12:42
Hot Stocks
Omnicom rises after winning $4B U.S. Army ad account »

Shares of Omnicom (OMC)…

OMC

Omnicom

$76.77

1.06 (1.40%)

WPP

WPP

$54.99

1.4 (2.61%)

F

Ford

$9.16

0.1 (1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 13

    Dec

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

RHT

Red Hat

$173.28

-0.22 (-0.13%)

, IBM

IBM

$118.90

1.73 (1.48%)

12:41
11/21/18
11/21
12:41
11/21/18
12:41
Periodicals
EC review of Red Hat-IBM deal to 'zoom in' on middleware, Dealreporter says »

The European Commission…

RHT

Red Hat

$173.28

-0.22 (-0.13%)

IBM

IBM

$118.90

1.73 (1.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 05

    Dec

  • 06

    Dec

  • 03

    Mar

AAL

American Airlines

$36.91

1.31 (3.68%)

12:36
11/21/18
11/21
12:36
11/21/18
12:36
Periodicals
American Airlines glitch briefly hampers travelers, USA Today reports »

A computer glitch in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOX

21st Century Fox

$48.54

0.22 (0.46%)

, FOXA

21st Century Fox

$48.84

0.25 (0.51%)

12:25
11/21/18
11/21
12:25
11/21/18
12:25
OnTheFly
Box Office Battle: 'Wreck-It Ralph' seen knocking out 'Beasts,' 'Creed' »

DISNEY EXPECTED TO WIN…

FOX

21st Century Fox

$48.54

0.22 (0.46%)

FOXA

21st Century Fox

$48.84

0.25 (0.51%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$37.34

0.59 (1.61%)

T

AT&T

$29.95

0.54 (1.84%)

DIS

Disney

$113.45

1.67 (1.49%)

VIA

Viacom

$35.28

1.06 (3.10%)

VIAB

Viacom

$31.82

1 (3.24%)

SNE

Sony

$50.75

1.21 (2.44%)

LGF.A

Lionsgate

$19.08

0.77 (4.21%)

LGF.B

Lionsgate

$17.64

0.78 (4.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 29

    Nov

  • 03

    Dec

  • 04

    Dec

AG

First Majestic

$5.52

0.28 (5.34%)

12:25
11/21/18
11/21
12:25
11/21/18
12:25
Options
First Majestic call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/21/18
11/21
12:17
11/21/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/21/18
11/21
12:16
11/21/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$177.79

0.69 (0.39%)

, DE

Deere

$143.72

5.23 (3.78%)

12:15
11/21/18
11/21
12:15
11/21/18
12:15
OnTheFly
Fly Intel: Wall Street's top stories at midday »

Stocks opened in positive…

AAPL

Apple

$177.79

0.69 (0.39%)

DE

Deere

$143.72

5.23 (3.78%)

GPS

Gap

$25.58

0.93 (3.77%)

FB

Facebook

$136.30

3.83 (2.89%)

TNDM

TNDM

BZUN

Baozun

$33.26

3.19 (10.61%)

FL

Foot Locker

$52.48

6.38 (13.84%)

JNJ

Johnson & Johnson

$142.00

-4.44 (-3.03%)

CAL

Caleres

$28.43

-2.5 (-8.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 21

    Nov

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 04

    Dec

  • 12

    Dec

  • 03

    Mar

NKTR

Nektar

$37.50

-0.7 (-1.83%)

12:05
11/21/18
11/21
12:05
11/21/18
12:05
Options
Nektar call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

HD

Home Depot

$170.35

1.18 (0.70%)

12:03
11/21/18
11/21
12:03
11/21/18
12:03
Hot Stocks
Home Depot director Mark Vadon purchases over $2M worth of company stock »

Home Depot director Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDY

Dr. Reddy's

$36.77

0.29 (0.79%)

, AQST

Aquestive Therapeutics

$9.71

-3.465 (-26.31%)

12:02
11/21/18
11/21
12:02
11/21/18
12:02
Recommendations
Dr. Reddy's, Aquestive Therapeutics analyst commentary  »

BMO says Aquestive loss…

RDY

Dr. Reddy's

$36.77

0.29 (0.79%)

AQST

Aquestive Therapeutics

$9.71

-3.465 (-26.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

AET

Aetna

$205.78

1.635 (0.80%)

, CVS

CVS Health

$75.77

0.25 (0.33%)

12:02
11/21/18
11/21
12:02
11/21/18
12:02
Hot Stocks
NJ state clears CVS-Aetna merger »

According to a filing,…

AET

Aetna

$205.78

1.635 (0.80%)

CVS

CVS Health

$75.77

0.25 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

12:01
11/21/18
11/21
12:01
11/21/18
12:01
General news
EIA natural gas storage change for week ending November 16 »

Gas inventories 134 Bcf…

GS

Goldman Sachs

$193.29

1.95 (1.02%)

11:55
11/21/18
11/21
11:55
11/21/18
11:55
Periodicals
Abu Dhabi fund sues Goldman Sachs over 1MDB scandal, FT says »

Abu Dhabi's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNHBF

ICC International Cannabis

$0.00

(0.00%)

, CGC

Canopy Growth

$34.08

2.17 (6.80%)

11:51
11/21/18
11/21
11:51
11/21/18
11:51
OnTheFly
Rising High: International Cannabis agrees to acquire Green Gene »

Welcome to "Rising High,"…

KNHBF

ICC International Cannabis

$0.00

(0.00%)

CGC

Canopy Growth

$34.08

2.17 (6.80%)

MMNFF

MedMen

$0.00

(0.00%)

ACB

Aurora Cannabis

$6.27

0.23 (3.81%)

CVSI

CV Sciences

$0.00

(0.00%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

CRON

Cronos Group

$8.57

0.38 (4.64%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$0.00

(0.00%)

TLRY

Tilray

$107.50

3.56 (3.43%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

CRM

Salesforce

$124.33

3.61 (2.99%)

11:50
11/21/18
11/21
11:50
11/21/18
11:50
Options
Put spread in Salesforce as shares bounce 3% »

Put spread in Salesforce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 06

    Dec

  • 11

    Dec

  • 03

    Mar

11:45
11/21/18
11/21
11:45
11/21/18
11:45
General news
Treasury's $11 B 10-year TIPS reopening was ok »

Treasury's $11 B…

11:45
11/21/18
11/21
11:45
11/21/18
11:45
General news
Atlanta Fed's Q4 GDPNow estimate was unchanged at 2.5% »

Atlanta Fed's Q4…

11:45
11/21/18
11/21
11:45
11/21/18
11:45
General news
Breaking General news story  »

Week of 11/16 EIA Natural…

AQST

Aquestive Therapeutics

$9.60

-3.57 (-27.11%)

, RDY

Dr. Reddy's

$36.89

0.41 (1.12%)

11:44
11/21/18
11/21
11:44
11/21/18
11:44
Recommendations
Aquestive Therapeutics, Dr. Reddy's analyst commentary  »

Aquestive selloff on…

AQST

Aquestive Therapeutics

$9.60

-3.57 (-27.11%)

RDY

Dr. Reddy's

$36.89

0.41 (1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.